Core Viewpoint - The announcement details the completion of a judicial auction of shares held by the controlling shareholder of Yuekang Pharmaceutical, which will not adversely affect the company's management or lead to changes in the controlling shareholder or actual controller [1]. Summary of Key Points 1. Basic Situation of Equity Change - The controlling shareholder, Jingyue Yongshun, auctioned 26,500,000 unrestricted circulating shares from July 14 to July 15, 2025, which were fully acquired by 12 individuals [1]. - The auction was conducted on the JD.com judicial auction platform, and the results were confirmed in a transaction confirmation document [1]. 2. Changes in Shareholding Structure - Prior to the equity change, Jingyue Yongshun held 180,240,120 shares, accounting for 40.05% of the total share capital. After the auction, their holdings decreased to 153,740,120 shares, representing 34.16% [2][4]. - The total shares held by Jingyue Yongshun and its concerted actions decreased from 245,447,562 shares (54.54%) to 218,947,562 shares (48.66%) [3][5]. 3. Nature of the Equity Change - The equity change is classified as a passive reduction due to a court ruling and does not trigger a mandatory tender offer [4]. - The buyers of the auctioned shares are restricted from selling these shares for six months following the acquisition, as per relevant regulations [4][6]. 4. Compliance and Disclosure - The company has informed all bidders of the restrictions on share reduction and will adhere to relevant laws and regulations regarding information disclosure [6].
悦康药业: 关于公司控股股东所持部分股份被司法拍卖完成过户登记暨权益变动跨越5%整数倍的提示性公告